PURPOSE: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. MATERIALS AND METHODS: Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36~87)) with available baseline values of albumin and beta(2)-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. RESULTS: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). CONCLUSION: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients.
PURPOSE: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myelomapatients. MATERIALS AND METHODS: Between 1992 and 2005, 85 multiple myelomapatients (men: women 41:44, median age: 63 years (range: 36~87)) with available baseline values of albumin and beta(2)-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. RESULTS: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). CONCLUSION: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myelomapatients.
Entities:
Keywords:
International Staging System; Multiple myeloma; Southwest Oncology Group staging system
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Vasileios I Sakellariou; Andreas F Mavrogenis; Olga Savvidou; Franklin H Sim; Panayiotis J Papagelopoulos Journal: Eur J Orthop Surg Traumatol Date: 2014-10-19
Authors: Angel T Chan; William Dinsfriend; Jiwon Kim; Brian Yum; Razia Sultana; Christopher A Klebanoff; Andrew Plodkowski; Rocio Perez Johnston; Michelle S Ginsberg; Jennifer Liu; Raymond J Kim; Richard Steingart; Jonathan W Weinsaft Journal: J Cardiovasc Magn Reson Date: 2021-04-05 Impact factor: 5.364